Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common type of cancers worldwide. However, current therapeutic approaches for this epidemic disease are limited, and its 5-year survival rate hasn't been improved in the past decades. Patient-derived xenograft (PDX) tumor models have become an ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shuqun, Luo, Chonglin, Gu, Qingyang, Xu, Qiang, Wang, Guan, Sun, Hongye, Qian, Ziliang, Tan, Yexiong, Qin, Yuxin, Shen, Yuhong, Xu, Xiaowei, Chen, Shu-Hui, Chan, Chi-Chung, Wang, Hongyang, Mao, Mao, Fang, Douglas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868698/
https://www.ncbi.nlm.nih.gov/pubmed/26701727
http://dx.doi.org/10.18632/oncotarget.6684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868698/
https://www.ncbi.nlm.nih.gov/pubmed/26701727
http://dx.doi.org/10.18632/oncotarget.6684

Ejemplares similares